Pharmacokinetics of ganciclovir during continuous venovenous hemodiafiltration in critically Ill patients

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 1, 2014, Pages 94-101

  Horvatits, Thomas ^a   Kitzberger, Reinhard ^a   Drolz, Andreas ^a   Zauner, Christian ^a   Jäger, Walter ^b   Böhmdorfer, Michaela ^b   Kraff, Stefanie ^c   Fritsch, Achim ^c   Thalhammer, Florian ^a   Fuhrmann, Valentin ^a   Schenk, Peter ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GANCICLOVIR;

ABSENCE OF SIDE EFFECTS; ACUTE KIDNEY FAILURE; ADULT; ANURIA; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CENTRAL VENOUS CATHETER; CLINICAL ARTICLE; CONTINUOUS HEMODIAFILTRATION; CONTROLLED STUDY; CREATININE CLEARANCE; CRITICALLY ILL PATIENT; CYTOMEGALOVIRUS INFECTION; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG HALF LIFE; DRUG TOLERABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAXIMUM PLASMA CONCENTRATION; MONTE CARLO METHOD; OPEN STUDY; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RENAL REPLACEMENT THERAPY; SINGLE DRUG DOSE;

AGED; ANTIVIRAL AGENTS; CRITICAL ILLNESS; FEMALE; GANCICLOVIR; HEMODIAFILTRATION; HUMANS; MALE; MIDDLE AGED; MONTE CARLO METHOD;

EID: 84891546733     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00892-13     Document Type: Article

References (38)

1. Crumpacker CS. 1996. Ganciclovir. N. Engl. J. Med. 335:721-729. http://dx.doi.org/10.1056/NEJM199609053351007.
2. Griffiths PD. 1997. Prophylaxis against CMV infection in transplant patients. J. Antimicrob. Chemother. 39:299-301. http://dx.doi.org/10.1093/jac/ 39.3.299.
3. McGavin JK, Goa KL. 2001. Ganciclovir: An update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients. Drugs 61:1153-1183. http://dx.doi.org/10.2165/00003495-200161080-00016.
4. Osawa R, Singh N. 2009. Cytomegalovirus infection in critically ill patients: A systematic review. Crit. Care 13:R68. http://dx.doi.org/10.1186/ cc7875.
5. Faulds D, Heel RC. 1990. Ganciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirusinfections. Drugs 39:597-638.
6. Nevins TE, Dunn DL. 1992. Use of ganciclovir for cytomegalovirus infection. J. Am. Soc. Nephrol. 2(12 Suppl):S270-S273.
7. Roche Laboratories, Inc. 2009. Cymevene (ganciclovir) package insert. Roche Laboratories, Inc, Basel, Switzerland.
8. Scott JC, Partovi N, Ensom MH. 2004. Ganciclovir in solid organ transplant recipients: Is there a role for clinical pharmacokinetic monitoring? Ther. Drug Monit. 26:68-77. http://dx.doi.org/10.1097/00007691-200402000-00014.
9. Wiltshire H, Paya CV, Pescovitz MD, Humar A, Dominguez E, Washburn K, Blumberg E, Alexander B, Freeman R, Heaton N, Zuideveld KP. 2005. Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients. Transplantation 79:1477-1483. http://dx.doi.org/10.1097/ 01.TP.0000164512.99703.AD.
10. Caldes A, Colom H, Armendariz Y, Garrido MJ, Troconiz IF, Gil- Vernet S, Lloberas N, Pou L, Peraire C, Grinyo JM. 2009. Population pharmacokinetics of ganciclovir after intravenous ganciclovir and oral valganciclovir administration in solid organ transplant patients infected with cytomegalovirus. Antimicrob. Agents Chemother. 53:4816-4824. http://dx.doi.org/10.1128/AAC.00085-09.
11. Ronco C, Bellomo R, Homel P, Brendolan A, Dan M, Piccinni P, La Greca G. 2000. Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: A prospective randomised trial. Lancet 356:26-30. http://dx.doi.org/10.1016/S0140-6736(00)02430-2.
12. Bohler J, Donauer J, Keller F. 1999. Pharmacokinetic principles during continuous renal replacement therapy: Drugs and dosage. Kidney Int. Suppl. 1999:S24 -S28.
13. Asano-Mori Y, Kanda Y, Oshima K, Watanabe T, Shoda E, Motokura T, Kurokawa M, Chiba S. 2006. Pharmacokinetics of ganciclovir in haematopoietic stem cell transplantation recipients with or without renal impairment. J. Antimicrob. Chemother. 57:1004-1007. http://dx.doi.org/10.1093/jac/dkl089.
14. Bailey TC, Trulock EP, Storch GA, Powderly WG. 1992. Ganciclovir for cytomegalovirus after heart transplantation. N. Engl. J. Med. 327:891.(Reply, 327:892-893.)
15. Fuhrmann V, Schenk P, Jaeger W, Miksits M, Kneidinger N, Warszawska J, Holzinger U, Kitzberger R, Thalhammer F. 2007. Pharmacokinetics of voriconazole during continuous venovenous haemodiafiltration. J. Antimicrob. Chemother. 60:1085-1090. http://dx.doi.org/10.1093/jac/dkm349.
16. Fuhrmann V, Schenk P, Jaeger W, Ahmed S, Thalhammer F. 2004. Pharmacokinetics of moxifloxacin in patients undergoing continuous venovenous haemodiafiltration. J. Antimicrob. Chemother. 54:780-784. http://dx.doi.org/10. 1093/jac/dkh421.
17. Studies of Ocular Complications of AIDS Research Group, AIDS Clinical Trials Group. 1992. Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. N. Engl. J. Med. 326:213-220. http://dx.doi.org/10.1056/ NEJM199201233260401.
18. Yuen GJ, Drusano GL, Fletcher C, Capparelli E, Connor JD, Lalezari JP, Drew L, Follansbee S, Busch D, Jacobson M, Spector SA, Squires K, Buhles W. 1995. Population differences in ganciclovir clearance as determined by nonlinear mixed-effects modelling. Antimicrob. Agents Chemother. 39:2350-2352. http://dx.doi.org/10.1128/AAC.39.10.2350.
19. Biron KK. 2006. Antiviral drugs for cytomegalovirus diseases. Antiviral Res. 71:154-163. http://dx.doi.org/10.1016/j.antiviral.2006.05.002.
20. McGloughlin S, Roberts JA, O'Donoghue S, Martin J, Briscoe S, Lipman J. 2011. Ganciclovir pharmacokinetics and suggested dosing in continuous venovenous haemodiafiltration. Int. J. Antimicrob. Agents 37: 90-92. http://dx.doi.org/10. 1016/j.ijantimicag.2010.10.003.
21. Gando S, Kameue T, Nanzaki S, Hayakawa T, Nakanishi Y. 1998. Pharmacokinetics and clearance of ganciclovir during continuous hemodiafiltration. Crit. Care Med. 26:184-187. http://dx.doi.org/10.1097/ 00003246-199801000-00038.
22. Cockcroft DW, Gault MH. 1976. Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41. http://dx.doi.org/10.1159/000180580.
23. Hudson JQ, Comstock TJ, Feldman GM. 2004. Evaluation of an in vitro dialysis system to predict drug removal. Nephrol. Dial. Transplant. 19: 400-405. http://dx.doi.org/10.1093/ndt/gfg550.
24. Thalhammer F, Rosenkranz AR, Burgmann H, Graninger W, Hollenstein U, Schenk P, Thalhammer-Scherrer R, Traindl O, Horl WH, Breyer S. 1997. Single-dose pharmacokinetics of teicoplanin during hemodialysis therapy using high-flux polysulfone membranes. Wien. Klin. Wochenschr. 109:362-365.
25. Agarwal R, Cronin RE. 1994. Heterogeneity in gentamicin clearance between high-efficiency hemodialyzers. Am. J. Kidney Dis. 23:47-51.
26. De Paepe P, Belpaire FM, Buylaert WA. 2002. Pharmacokinetic and pharmacodynamic considerations when treating patients with sepsis and septic shock. Clin. Pharmacokinet. 41:1135-1151. http://dx.doi.org/10.2165/00003088- 200241140-00002.
27. Bugge JF. 2001. Pharmacokinetics and drug dosing adjustments during continuous venovenous hemofiltration or hemodiafiltration in critically ill patients. Acta Anaesthesiol. Scand. 45:929-934. http://dx.doi.org/10.1034/j. 1399-6576.2001.450802.x.
28. Plotkin SA, Drew WL, Felsenstein D, Hirsch MS. 1985. Sensitivity of clinical isolates of human cytomegalovirus to 9-(1,3-dihydroxy-2- propoxymethyl)guanine. J. Infect. Dis. 152:833-834. http://dx.doi.org/10.1093/ infdis/152.4.833.
29. Emery VC, Griffiths PD. 2000. Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy. Proc. Natl. Acad. Sci. U. S. A. 97:8039-8044. http://dx.doi.org/10.1073/pnas.140123497.
30. Tomaselli F, Dittrich P, Maier A, Woltsche M, Matzi V, Pinter J, Nuhsbaumer S, Pinter H, Smolle J, Smolle-Juttner FM. 2003. Penetration of piperacillin and tazobactam into pneumonic human lung tissue measured by in vivo microdialysis. Br. J. Clin. Pharmacol. 55:620-624. http://dx.doi.org/10.1046/j. 1365-2125.2003.01797.x.
31. Hutschala D, Skhirtladze K, Zuckermann A, Wisser W, Jaksch P, Mayer-Helm BX, Burgmann H, Wolner E, Muller M, Tschernko EM. 2005. In vivo measurement of levofloxacin penetration into lung tissue after cardiac surgery. Antimicrob. Agents Chemother. 49:5107-5111. http://dx.doi.org/10.1128/AAC.49.12.5107-5111. 2005.
32. Bastien O, Boulieu R, Bleyzac N, Estanove S. 1994. Clinical use of ganciclovir during renal failure and continuous hemodialysis. Intensive Care Med. 20:47-48. http://dx.doi.org/10.1007/BF02425056.
33. Fletcher C, Sawchuk R, Chinnock B, de Miranda P, Balfour HH, Jr. 1986. Human pharmacokinetics of the antiviral drug DHPG. Clin. Pharmacol. Ther. 40:281-286. http://dx.doi.org/10.1038/clpt.1986.177.
34. Boulieu R, Bastien O, Bleyzac N. 1993. Pharmacokinetics of ganciclovir in heart transplant patients undergoing continuous venovenous hemodialysis. Ther. Drug Monit. 15:105-107. http://dx.doi.org/10.1097/00007691-199304000-00006.
35. Benet LZ, Galeazzi RL. 1979. Noncompartmental determination of the steady-state volume of distribution. J. Pharm. Sci. 68:1071-1074. http://dx.doi.org/10.1002/jps.2600680845.
36. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, Machado FR, Rubenfeld GD, Webb S, Beale RJ, Vincent JL, Moreno R. 2013. Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med. 39:165-228. http://dx.doi.org/10.1007/s00134-012-2769-8.
37. Janoly-Dumenil A, Rouvet I, Bleyzac N, Bertrand Y, Aulagner G, Zabot MT. 2009. Effect of duration and intensity of ganciclovir exposure on lymphoblastoid cell toxicity. Antivir. Chem. Chemother. 19:257-262.
38. Swan SK, Munar MY, Wigger MA, Bennett WM. 1991. Pharmacokinetics of ganciclovir in a patient undergoing hemodialysis. Am. J. Kidney Dis. 17:69-72.